Developing and deploying genomics technologies in support of cancer and life sciences research.

Canada's Michael Smith Genome Sciences Centre (GSC) at BC Cancer is an international leader in genomics, proteomics and bioinformatics for precision medicine. By developing and deploying cutting-edge genome sequencing, computational and analytical technology, we are creating novel strategies to prevent and diagnose cancers and other diseases, uncovering new therapeutic targets and helping the world realize the social and economic benefits of genome science. 

Our Technology Platform

The GSC is available to support your research. We guide experimental design, facilitate the processing of complex biological samples and provide numerous sequencing and bioinformatic services with the aim of making genomics accessible to the international scientific community. Explore our technology platforms and services, and if you have questions or would like to collaborate please fill out our contact form or speak directly with one of our platform leaders.

The GSC is ISO27001 certified for information security management.

Our Scientific Research

The 13 faculty members at the GSC have a diverse range of expertise in genomics, bioinformatics, proteomics, epigenomics, immunogenetics, cancer biology, computer science and software development. Together, we apply our knowledge to advance the global understanding of cancer and other diseases with an ultimate aim toward improving human health through disease prevention, the development of novel diagnostic strategies and by uncovering new therapeutic approaches, all the while helping the world to realize the social and economic benefits of genome research.

Our Clinical Programs

The GSC is unique in that it fosters close collaborations between scientists and clinicians, allowing for an unencumbered focus on direct translational research. Through the Personalized OncoGenomics (POG) program, the GSC deploys whole genome and transcriptome sequencing to inform therapeutic and management strategies for late-stage cancer patients in real time. The GSC is also certified by the College of American Pathologists (CAP) and the Diagnostic Accreditation Program (DAP) to perform clinical genomic panel testing.

Questions?

Please feel free to speak with one of our Platform Leaders directly:

Directors & Platform Leaders

News

Sep 03, 2020

A bioinformatics method may help uncover link between immune system variability and SARS-CoV-2 susceptibility

The striking variability in disease severity in people infected with SARS-CoV-2 has been attributed to several host factors, including age, pre-existing health conditions and differences in host genetics and immune responses. In a study published in the journal Bioinformatics, Dr. Inanc Birol and René Warren demonstrated the technical feasibility and utility of the bioinformatics tool, HLAminer, to investigate the role of host immune system variability in COVID-19 disease susceptibility.
Aug 27, 2020

New tool enables researchers to assemble transcript isoforms from single cells

The advent of single-cell RNA sequencing technologies has provided unprecedented opportunities for the analysis of transcriptomes at single-cell resolution, allowing researchers to explore cell-to-cell variability. Now, researchers have developed a tool for the analysis and identification of RNA isoforms from single-cell RNA sequencing data. 

Publications

Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade–specific epigenome and transcriptome landscapes

Nature Genetics, 2020
Alessia Gagliardi, Vanessa L Porter, Zusheng Zong, Reanne Bowlby, Emma Titmuss, Constance Namirembe, Nicholas B Griner, Hilary Petrello, Jay Bowen, Simon K Chan, Luka Culibrk, Teresa M Darragh, Mark H Stoler, Thomas C Wright, Patee Gesuwan, Maureen A Dyer, Yussanne Ma, Karen L Mungall, Steven J M Jones, Carolyn Nakisige, Karen Novik, Jackson Orem, Martin Origa, Julie M Gastier-Foster, Robert Yarchoan, Corey Casper, Gordon B Mills, Janet S Rader, Akinyemi I Ojesina, Daniela S Gerhard, Andrew J Mungall, Marco A Marra
Back to top